DNA interstrand crosslink repair and cancer
暂无分享,去创建一个
[1] L. Goodman,et al. NITROGEN MUSTARD THERAPY: Use of Methyl-Bis(Beta-Chloroethyl)amine Hydrochloride and Tris(Beta-Chloroethyl)amine Hydrochloride for Hodgkin's Disease, Lymphosarcoma, Leukemia and Certain Allied and Miscellaneous Disorders , 1946 .
[2] L. Kanter,et al. Nitrogen mustard therapy; clinical studies on the effects of methyl-bis (beta-chloroethyl) amine hydrochloride upon various types of neoplastic disease. , 1949, American journal of surgery.
[3] G. Fanconi. Familial constitutional panmyelocytopathy, Fanconi's anemia (F.A.). I. Clinical aspects. , 1967, Seminars in hematology.
[4] W. Schmid. Familial constitutional panmyelocytopathy, Fanconi's anemia (F.A.). II. A discussion of the cytogenetic findings in Fanconi's anemia. , 1967, Seminars in hematology.
[5] A. Morley,et al. Cyclophosphamide-induced cyclical neutropenia. An animal model of a human periodic disease. , 1970, The New England journal of medicine.
[6] J. Affeldt,et al. The feasibility study , 2019, The Information System Consultant’s Handbook.
[7] J. German,et al. A manyfold increase in sister chromatid exchanges in Bloom's syndrome lymphocytes. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[8] H. C. Harder,et al. Template primer inactivation by cis- and trans-dichlorodiammine platinum for human DNA polymerase alpha, beta, and Rauscher murine leukemia virus reverse transcriptase, as a mechanism of cytotoxicity. , 1976, Cancer research.
[9] M. Ashwood‐Smith,et al. 5-Methoxypsoralen, an ingredient in several suntan preparations, has lethal, mutagenic and clastogenic properties , 1980, Nature.
[10] S. Latt. Sister chromatid exchange formation. , 1981, Annual review of genetics.
[11] A. Eastman. Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). , 1983, Biochemistry.
[12] D. Stoll,et al. Hematologic toxicity of cisplatin and mitoraycin in combination for squamous cell carcinoma of esophagus , 1985, American journal of clinical oncology.
[13] A. Eastman. Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. , 1986, Biochemistry.
[14] D. Lydall,et al. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. , 1986, Cancer research.
[15] J. Dunnick,et al. Toxicity of 8-methoxypsoralen, 5-methoxypsoralen, 3-carbethoxypsoralen, or 5-methylisopsoralen with ultraviolet radiation in the hairless (HRA/Skh) mouse. , 1987, Toxicology and applied pharmacology.
[16] M. Tucker,et al. Risk of second cancers after treatment for Hodgkin's disease. , 1988, The New England journal of medicine.
[17] A. Auerbach. A test for Fanconi's anemia [letter] , 1988 .
[18] A. Auerbach. A test for Fanconi's anemia. , 1988, Blood.
[19] S. Caplan,et al. Correlation of resistance to nitrogen mustards in chronic lymphocytic leukemia with enhanced removal of melphalan-induced DNA cross-links. , 1989, Biochemical pharmacology.
[20] K. Wolff. Side‐effects of psoralen photochemotherapy (PUVA) , 1990, The British journal of dermatology.
[21] J. Dijkstra,et al. Severe phototoxic burn following celery ingestion. , 1992, Archives of dermatology.
[22] V. Bohr,et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. , 1992, Journal of the National Cancer Institute.
[23] A. Collins,et al. Mutant rodent cell lines sensitive to ultraviolet light, ionizing radiation and cross-linking agents: a comprehensive survey of genetic and biochemical characteristics. , 1993, Mutation research.
[24] A. Griffith,et al. Binding of Ku protein to DNA. Measurement of affinity for ends and demonstration of binding to nicks. , 1993, The Journal of biological chemistry.
[25] D. Papadopoulo,et al. Frequencies of HPRT- lymphocytes and glycophorin A variants erythrocytes in Fanconi anemia patients, their parents and control donors. , 1993, Mutation research.
[26] David P. Rall,et al. Veterans at Risk : the health effects of mustard gas and Lewisite , 1993 .
[27] S. Jackson,et al. The DNA-dependent protein kinase: Requirement for DNA ends and association with Ku antigen , 1993, Cell.
[28] R. Gale,et al. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. , 1994, Blood.
[29] D. Slamon,et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. , 1994, Oncogene.
[30] Huifang Huang,et al. Solution Structure of a Cisplatin-Induced DNA Interstrand Cross-Link , 1995, Science.
[31] J. Hearst,et al. Solution structures of psoralen monoadducted and cross-linked DNA oligomers by NMR spectroscopy and restrained molecular dynamics. , 1995, Biochemistry.
[32] G. S. Kumar,et al. Structural and function modification of DNA by mitomycin C. Mechanism of the DNA sequence specificity of mitomycins. , 1995, Nucleic acids symposium series.
[33] B. Sanderson,et al. Mutagenic damage to mammalian cells by therapeutic alkylating agents. , 1996, Mutation research.
[34] T. Glover,et al. FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. , 1996, Human molecular genetics.
[35] S. Aebi,et al. The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.
[36] E. Cundari,et al. Deregulated apoptosis is a hallmark of the Fanconi anemia syndrome. , 1997, Cancer research.
[37] S. Elledge,et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. , 1997, Science.
[38] E. A. Zottola,et al. Isolation and identification of antimicrobial furocoumarins from parsley. , 1997, Journal of food protection.
[39] A. Fattorossi,et al. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] P. Hall,et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. , 1999, The New England journal of medicine.
[41] David J. Chen,et al. DNA Interstrand Cross-Links Induce Futile Repair Synthesis in Mammalian Cell Extracts , 2000, Molecular and Cellular Biology.
[42] B. Cheson,et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[43] A. Bradley,et al. Cancer predisposition caused by elevated mitotic recombination in Bloom mice , 2000, Nature Genetics.
[44] R. Weichselbaum,et al. The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin* , 2000, The Journal of Biological Chemistry.
[45] C. Lewis,et al. Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group. , 2000, Blood.
[46] S. Johnson,et al. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. , 2000, Biochemical pharmacology.
[47] S. Kim,et al. Effect of Vinorelbine, Ifosfamide, and Cisplatin Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer , 2000, American journal of clinical oncology.
[48] A. Cuddihy,et al. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells , 2001, Oncogene.
[49] S. Powell,et al. Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2. , 2001, Cancer research.
[50] S. Ganesan,et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. , 2001, Molecular cell.
[51] B. Beverloo,et al. The structure‐specific endonuclease Ercc1—Xpf is required for targeted gene replacement in embryonic stem cells , 2001, The EMBO journal.
[52] C. Kemp,et al. Synthetic lethality between mutation in Atm and DNA-PKcs during murine embryogenesis , 2001, Current Biology.
[53] A. Noronha,et al. Solution structure of a DNA duplex containing mispair-aligned N4C-ethyl-N4C interstrand cross-linked cytosines. , 2002, Biochemistry.
[54] M. Lopes,et al. Fork Reversal and ssDNA Accumulation at Stalled Replication Forks Owing to Checkpoint Defects , 2002, Science.
[55] Ian D. Hickson,et al. The Bloom's syndrome helicase suppresses crossing over during homologous recombination , 2003, Nature.
[56] H. Broxmeyer,et al. Retroviral-mediated expression of recombinant Fancc enhances the repopulating ability of Fancc-/- hematopoietic stem cells and decreases the risk of clonal evolution. , 2003, Blood.
[57] J. Satagopan,et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. , 2003, Journal of the National Cancer Institute.
[58] L. Nechev,et al. DNA interchain cross-links formed by acrolein and crotonaldehyde. , 2003, Journal of the American Chemical Society.
[59] K. Kamiya,et al. Structure and Enzymatic Properties of a Stable Complex of the Human REV1 and REV7 Proteins* , 2003, The Journal of Biological Chemistry.
[60] M. Selvakumaran,et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. , 2003, Cancer research.
[61] Weidong Wang,et al. A Multiprotein Nuclear Complex Connects Fanconi Anemia and Bloom Syndrome , 2003, Molecular and Cellular Biology.
[62] J. Shah,et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. , 2003, Archives of otolaryngology--head & neck surgery.
[63] R. L. Baldwin,et al. Improved survival in women with BRCA‐associated ovarian carcinoma , 2003, Cancer.
[64] P. Rosenberg,et al. Cancer incidence in persons with Fanconi anemia. , 2003, Blood.
[65] R. Baer,et al. The BRCA1/BARD1 Heterodimer Assembles Polyubiquitin Chains through an Unconventional Linkage Involving Lysine Residue K6 of Ubiquitin* , 2003, Journal of Biological Chemistry.
[66] C. Mathew,et al. Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors , 2003, Nature Medicine.
[67] J. Rocha,et al. A High Fat Diet Inhibits δ-Aminolevulinate Dehydratase and Increases Lipid Peroxidation in Mice (Mus musculus) , 2003 .
[68] W. Ebell,et al. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor. , 2003, Blood.
[69] Yunmei Ma,et al. Mechanism and regulation of human non-homologous DNA end-joining , 2003, Nature Reviews Molecular Cell Biology.
[70] David J. Chen,et al. Complex Formation by the Human Rad51B and Rad51C DNA Repair Proteins and Their Activities in Vitro * , 2002, The Journal of Biological Chemistry.
[71] Stephen C. West,et al. Molecular views of recombination proteins and their control , 2003, Nature Reviews Molecular Cell Biology.
[72] Alan Gordon,et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.
[73] J. Satagopan,et al. Re: Human Papillomavirus DNA and p53 Polymorphisms in Squamous Cell Carcinomas From Fanconi Anemia Patients , 2004 .
[74] David J. Chen,et al. Human Rad51C Deficiency Destabilizes XRCC3, Impairs Recombination, and Radiosensitizes S/G2-phase Cells* , 2004, Journal of Biological Chemistry.
[75] Guido Kroemer,et al. Cell death by mitotic catastrophe: a molecular definition , 2004, Oncogene.
[76] W. Eiermann,et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. , 2004, Journal of the National Cancer Institute.
[77] J. Cooper,et al. Two modes of DNA double-strand break repair are reciprocally regulated through the fission yeast cell cycle. , 2004, Genes & development.
[78] N. James,et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer , 2004, British Journal of Cancer.
[79] A. D’Andrea,et al. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. , 2004, Blood.
[80] A. D’Andrea,et al. Functional Interaction of Monoubiquitinated FANCD2 and BRCA2/FANCD1 in Chromatin , 2004, Molecular and Cellular Biology.
[81] J. Hoeijmakers,et al. Fanconi Anemia (Cross)linked to DNA Repair , 2005, Cell.
[82] B. Engelward,et al. Interstrand crosslink-induced homologous recombination carries an increased risk of deletions and insertions. , 2005, DNA repair.
[83] P. J. Brooks,et al. DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis. , 2005, Alcohol.
[84] Yasufumi Kaneda,et al. Rad51 siRNA delivered by HVJ envelope vector enhances the anti‐cancer effect of cisplatin , 2005, The journal of gene medicine.
[85] M. Pacek,et al. Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. , 2005, Genes & development.
[86] L. Collette,et al. Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer , 2005, Oncology.
[87] C. Mathew,et al. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M , 2005, Nature Genetics.
[88] P. Viens,et al. High-dose alkylating agents with autologous hematopoietic stem cell support and trastuzumab in ERBB2 overexpressing metastatic breast cancer: a feasibility study. , 2005, Anticancer research.
[89] M. Frankenberg-Schwager,et al. Cisplatin-mediated DNA double-strand breaks in replicating but not in quiescent cells of the yeast Saccharomyces cerevisiae. , 2005, Toxicology.
[90] H. Kitao,et al. A FancD2-monoubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair. , 2005, Molecular cell.
[91] T. Kuzel,et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. , 2005, Archives of dermatology.
[92] J. Hoeijmakers,et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis , 2006, Nature.
[93] F. Colland,et al. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP , 2006, Nature Cell Biology.
[94] S. Monfardini,et al. Oxaliplatin-related neurotoxicity: how and why? , 2006, Critical reviews in oncology/hematology.
[95] A. Gartner,et al. Excess Mcm2–7 license dormant origins of replication that can be used under conditions of replicative stress , 2006, The Journal of cell biology.
[96] D. Reinberg,et al. Histone H2B Monoubiquitination Functions Cooperatively with FACT to Regulate Elongation by RNA Polymerase II , 2006, Cell.
[97] Katsuhiro Hanada,et al. The structure‐specific endonuclease Mus81–Eme1 promotes conversion of interstrand DNA crosslinks into double‐strands breaks , 2006, The EMBO journal.
[98] D. Slamon,et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] Leslie L Robison,et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] S. Sarkar,et al. DNA interstrand crosslink repair during G1 involves nucleotide excision repair and DNA polymerase ζ , 2006, The EMBO journal.
[101] L. Thompson,et al. The Fanconi anemia pathway limits the severity of mutagenesis. , 2006, DNA repair.
[102] I. Hickson,et al. DNA helicases required for homologous recombination and repair of damaged replication forks. , 2006, Annual review of genetics.
[103] P. Rosenberg,et al. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2 , 2006, Journal of Medical Genetics.
[104] Anastasia Nijnik,et al. DNA repair is limiting for haematopoietic stem cells during ageing , 2007, Nature.
[105] S. Elledge,et al. Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair , 2007, Cell.
[106] B. Pégourié,et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial , 2007, The Lancet.
[107] Michael B Yaffe,et al. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. , 2007, Cancer cell.
[108] S. West,et al. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. , 2007, Molecular cell.
[109] G. Chowdhury,et al. Interstrand cross-links generated by abasic sites in duplex DNA. , 2007, Journal of the American Chemical Society.
[110] C. Mathew,et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer , 2007, Nature Genetics.
[111] Daniel A. Koster,et al. Antitumour drugs impede DNA uncoiling by topoisomerase I , 2007, Nature.
[112] J. Hoeijmakers,et al. First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. , 2007, American journal of human genetics.
[113] Alexander Rich,et al. Characterization of Z-DNA as a nucleosome-boundary element in yeast Saccharomyces cerevisiae , 2007, Proceedings of the National Academy of Sciences.
[114] L. Niedernhofer. The Fanconi anemia signalosome anchor. , 2007, Molecular cell.
[115] M. Stone. Interstrand DNA Cross‐Links Induced by α,β‐Unsaturated Aldehydes Derived from Lipid Peroxidation and Environmental Sources , 2008 .
[116] A. Noronha,et al. Distortion-dependent unhooking of interstrand cross-links in mammalian cell extracts. , 2008, Biochemistry.
[117] A. Constantinou,et al. Remodeling of DNA replication structures by the branch point translocase FANCM , 2008, Proceedings of the National Academy of Sciences.
[118] S. West,et al. Structural and functional relationships of the XPF/MUS81 family of proteins. , 2008, Annual review of biochemistry.
[119] K. Mitani. [Myelodysplastic syndrome]. , 2020, Nihon rinsho. Japanese journal of clinical medicine.
[120] A. D’Andrea,et al. The Fanconi anemia core complex is required for efficient point mutagenesis and Rev1 foci assembly. , 2008, DNA repair.
[121] C. R. Leemans,et al. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. , 2008, Journal of the National Cancer Institute.
[122] A. Gurtan,et al. Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24. , 2008, Blood.
[123] R. Aitken,et al. Impact of estrogenic compounds on DNA integrity in human spermatozoa: evidence for cross-linking and redox cycling activities. , 2008, Mutation research.
[124] Jingchuan Sun,et al. Mechanism of Replication-Coupled DNA Interstrand Crosslink Repair , 2008, Cell.
[125] Carmen L. Wilson,et al. A report from the Childhood Cancer Survivor Study (CCSS): cancer related posttraumatic stress symptoms, depression, anxiety, and chronic pain in adult childhood cancer survivors , 2009 .
[126] T. Glover,et al. Functional Interaction between the Fanconi Anemia D2 Protein and Proliferating Cell Nuclear Antigen (PCNA) via a Conserved Putative PCNA Interaction Motif* , 2009, The Journal of Biological Chemistry.
[127] P. Sung,et al. FANCI Binds Branched DNA and Is Monoubiquitinated by UBE2T-FANCL* , 2009, The Journal of Biological Chemistry.
[128] T. Gajewski,et al. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma , 2010, Cancer Chemotherapy and Pharmacology.
[129] C. Ponting,et al. Coordination of structure-specific nucleases by human SLX4/BTBD12 is required for DNA repair. , 2009, Molecular cell.
[130] N. Kohno,et al. Functional evidence for Eme1 as a marker of cisplatin resistance , 2009, International journal of cancer.
[131] David A. Williams,et al. Identification and characterization of mutations in FANCL gene: A second case of Fanconi anemia belonging to FA‐L complementation group , 2009, Human mutation.
[132] K. Vasquez,et al. Mismatch repair and nucleotide excision repair proteins cooperate in the recognition of DNA interstrand crosslinks , 2009, Nucleic acids research.
[133] T. Helleday,et al. The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links , 2009, Nucleic acids research.
[134] Andrzej Stasiak,et al. MRE11–RAD50–NBS1 is a critical regulator of FANCD2 stability and function during DNA double‐strand break repair , 2009, The EMBO journal.
[135] Min Huang,et al. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. , 2009, Developmental cell.
[136] A. Consiglio,et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells , 2009, Nature.
[137] J. Gautier,et al. Checkpoint signaling from a single DNA interstrand crosslink. , 2009, Molecular cell.
[138] M. Kris,et al. A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors , 2010, Cancer Chemotherapy and Pharmacology.
[139] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[140] Steven P. Gygi,et al. Mammalian BTBD12/SLX4 Assembles A Holliday Junction Resolvase and Is Required for DNA Repair , 2009, Cell.
[141] J. O’Shaughnessy,et al. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer , 2009, Breast Cancer Research and Treatment.
[142] Myriam Alcalay,et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells , 2009, Nature.
[143] O. Lipatov,et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[144] J. Diffley,et al. Concerted Loading of Mcm2–7 Double Hexamers around DNA during DNA Replication Origin Licensing , 2009, Cell.
[145] K. J. Patel,et al. Monoubiquitylation in the Fanconi anemia DNA damage response pathway. , 2009, DNA repair.
[146] A. D’Andrea,et al. DNA Polymerase POLN Participates in Cross-Link Repair and Homologous Recombination , 2009, Molecular and Cellular Biology.
[147] S. West,et al. FANCM connects the genome instability disorders Bloom's Syndrome and Fanconi Anemia. , 2009, Molecular cell.
[148] Maximina H. Yun,et al. CtIP-BRCA1 modulates the choice of DNA double-strand break repair pathway throughout the cell cycle , 2009, Nature.
[149] P. Sung,et al. MHF1-MHF2, a histone-fold-containing protein complex, participates in the Fanconi anemia pathway via FANCM. , 2010, Molecular cell.
[150] Weidong Wang,et al. A histone-fold complex and FANCM form a conserved DNA-remodeling complex to maintain genome stability. , 2010, Molecular cell.
[151] J Wade Harper,et al. A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. , 2010, Molecular cell.
[152] M. Hengartner,et al. Deficiency of FANCD2-Associated Nuclease KIAA1018/FAN1 Sensitizes Cells to Interstrand Crosslinking Agents , 2010, Cell.
[153] Dieter Niederacher,et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.
[154] Jeremy M. Stark,et al. 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks , 2010, Cell.
[155] Z. Szallasi,et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[156] L. Karnitz,et al. RAD18-mediated ubiquitination of PCNA activates the Fanconi anemia DNA repair network , 2010, The Journal of cell biology.
[157] S. Kowalczykowski,et al. Purified human BRCA2 stimulates RAD51-mediated recombination , 2010, Nature.
[158] M. Sivasubramaniam,et al. Ku70 Corrupts DNA Repair in the Absence of the Fanconi Anemia Pathway , 2010, Science.
[159] Kay Hofmann,et al. Identification of KIAA1018/FAN1, a DNA Repair Nuclease Recruited to DNA Damage by Monoubiquitinated FANCD2 , 2010, Cell.
[160] S. Duensing,et al. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. , 2010, Cancer research.
[161] A. Noronha,et al. Cross-link structure affects replication-independent DNA interstrand cross-link repair in mammalian cells. , 2010, Biochemistry.
[162] S. West,et al. The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA , 2010, Nature Structural &Molecular Biology.
[163] Franca Fraternali,et al. Mutation of the RAD51C gene in a Fanconi anemia–like disorder , 2010, Nature Genetics.
[164] M. Lopes,et al. Rad51 protects nascent DNA from Mre11 dependent degradation and promotes continuous DNA synthesis , 2010, Nature Structural &Molecular Biology.
[165] Z. Hořejší,et al. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. , 2010, Molecular cell.
[166] O. Schärer,et al. Translesion DNA synthesis polymerases in DNA interstrand crosslink repair , 2010, Environmental and molecular mutagenesis.
[167] H. Walden,et al. Ubiquitin signalling in DNA replication and repair , 2010, Nature Reviews Molecular Cell Biology.
[168] A. Auerbach,et al. Mutations of the SLX4 gene in Fanconi anemia , 2011, Nature Genetics.
[169] A. Figuera,et al. Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. , 2011, Blood.
[170] F. Sigaux,et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. , 2011, Blood.
[171] R. Wood,et al. DNA polymerases and cancer , 2011, Nature Reviews Cancer.
[172] R. Winqvist,et al. Using mouse models to investigate the biological and physiological consequences of defects in the Fanconi anaemia/breast cancer DNA repair signalling pathway , 2011, Journal of Pathology.
[173] S. West,et al. Aberrant chromosome morphology in human cells defective for Holliday junction resolution , 2011, Nature.
[174] D. Schindler,et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype , 2011, Nature Genetics.
[175] J. Soulier,et al. Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. , 2011, The Journal of clinical investigation.